Yanran Hu1,2,3, Yixiang Xu3, Yuchen Zheng3, Qing Kang3, Zhongze Lou2, Qiang Liu3, Han Chen3, Yunxin Ji2, Lei Guo3, Chen Chen3, Liemin Ruan4, Jue Chen5. 1. Medical School of Ningbo University, 818 Fenghua Road, Ningbo, 315211, Zhejiang, People's Republic of China. 2. Department of Psychosomatic Medicine, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, 315010, Zhejiang, People's Republic of China. 3. Department of Clinical Psychology, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Road, Shanghai, 200030, People's Republic of China. 4. Department of Psychosomatic Medicine, Ningbo First Hospital, No. 59 Liuting Street, Ningbo, 315010, Zhejiang, People's Republic of China. lmruan@tom.com. 5. Department of Clinical Psychology, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 Wan Ping Nan Road, Shanghai, 200030, People's Republic of China. chenjue2088@163.com.
Abstract
PURPOSE: Asprosin is a centrally acting appetite-promoting hormone and promotes glucose production in the liver. This study is the first to investigate the difference in asprosin in the plasma between anorexia nervosa (AN) and healthy controls, and to explore the relationship between asprosin changes and plasma glucose levels and AN symptoms. METHODS: Plasma asprosin and glucose concentrations were detected in AN patients (n = 46) and healthy control subjects (n = 47). Eating Disorder Inventory-2 (EDI-2) was used to assess subjects' eating disorder symptoms and related personality traits. The patient's concomitant levels of depression and anxiety were also measured using the beck depression inventory and beck anxiety inventory, respectively. RESULTS: Results indicate that AN patients had a higher asprosin concentration in their plasma compared to healthy controls (p = 0.033). Among AN patients, plasma asprosin levels correlated positively with EDI-2 interoceptive awareness subscale score (p = 0.030) and negatively with duration of illness (p = 0.036). Multiple linear regression analyses showed that increases in asprosin levels (p = 0.029), glucose levels (p = 0.024) and body mass index (p = 0.003) were associated with an increase of the score of EDI-2 bulimia subscale. CONCLUSIONS: Our findings suggest that the increase in plasma asprosin concentration in patients with AN may be a compensation for the body's energy shortage, and asprosin may be involved in the development of bulimia and lack of interoceptive awareness in AN patients. LEVEL OF EVIDENCE: Level III, case-control analytic study.
PURPOSE:Asprosin is a centrally acting appetite-promoting hormone and promotes glucose production in the liver. This study is the first to investigate the difference in asprosin in the plasma between anorexia nervosa (AN) and healthy controls, and to explore the relationship between asprosin changes and plasma glucose levels and AN symptoms. METHODS: Plasma asprosin and glucose concentrations were detected in ANpatients (n = 46) and healthy control subjects (n = 47). Eating Disorder Inventory-2 (EDI-2) was used to assess subjects' eating disorder symptoms and related personality traits. The patient's concomitant levels of depression and anxiety were also measured using the beck depression inventory and beck anxiety inventory, respectively. RESULTS: Results indicate that ANpatients had a higher asprosin concentration in their plasma compared to healthy controls (p = 0.033). Among ANpatients, plasma asprosin levels correlated positively with EDI-2 interoceptive awareness subscale score (p = 0.030) and negatively with duration of illness (p = 0.036). Multiple linear regression analyses showed that increases in asprosin levels (p = 0.029), glucose levels (p = 0.024) and body mass index (p = 0.003) were associated with an increase of the score of EDI-2 bulimia subscale. CONCLUSIONS: Our findings suggest that the increase in plasma asprosin concentration in patients with AN may be a compensation for the body's energy shortage, and asprosin may be involved in the development of bulimia and lack of interoceptive awareness in ANpatients. LEVEL OF EVIDENCE: Level III, case-control analytic study.
Authors: Anna Aulinas; Franziska Plessow; Reitumetse L Pulumo; Elisa Asanza; Christopher J Mancuso; Meghan Slattery; Christiane Tolley; Jennifer J Thomas; Kamryn T Eddy; Karen K Miller; Anne Klibanski; Madhusmita Misra; Elizabeth A Lawson Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Kamryn T Eddy; Elizabeth A Lawson; Christina Meade; Erinne Meenaghan; Sarah E Horton; Madhusmita Misra; Anne Klibanski; Karen K Miller Journal: J Clin Psychiatry Date: 2015-01 Impact factor: 4.384
Authors: Andrea L Utz; Elizabeth A Lawson; Madhusmita Misra; Diane Mickley; Suzanne Gleysteen; David B Herzog; Anne Klibanski; Karen K Miller Journal: Bone Date: 2008-03-25 Impact factor: 4.398
Authors: Elizabeth A Lawson; Laura M Holsen; Rebecca Desanti; McKale Santin; Erinne Meenaghan; David B Herzog; Jill M Goldstein; Anne Klibanski Journal: Eur J Endocrinol Date: 2013-10-01 Impact factor: 6.664
Authors: Samantha J Brooks; Gareth J Barker; Owen G O'Daly; Michael Brammer; Steven C R Williams; Christian Benedict; Helgi B Schiöth; Janet Treasure; Iain C Campbell Journal: BMC Psychiatry Date: 2011-11-17 Impact factor: 3.630
Authors: Asmaa Elnagar; Khalifa El-Dawy; Hussein I El-Belbasi; Ibrahim F Rehan; Hamdy Embark; Zeinab Al-Amgad; Obeid Shanab; Elsayed Mickdam; Gaber E Batiha; Salman Alamery; Samer S Fouad; Simona Cavalu; Mohammed Youssef Journal: Front Public Health Date: 2022-04-07